Katherine L. Byar, MSN, ANP-BC, BMTCN
Oncology Nurse Practitioner
University of Nebraska Medical Center
Omaha, Nebraska

Katherine Byar, MSN, APRN-BC, BMTCN® is a nurse practitioner in oncology at Nebraska Medicine where she provides care to oncology patients, both inpatient and outpatient.  Her passion is caring for patients with hematological malignancies; along with educating and mentoring other healthcare providers related to this area.

She received her Bachelor of Science in Nursing from Nebraska Methodist College in Omaha and Master of Science in Nursing at the University of Nebraska Medical Center. She is certified as an ANP-BC from ANCC and a Bone Marrow Transplant Certified Nurse (BMTCN) from Oncology Nursing Society (ONS).

She is currently a co-editor for ONS Cancer Basics Edition 3 textbook. She has written several book chapters, co-authored numerous articles and posters and has lectured extensively on a variety of oncology related topics. She is an active member of ONS, ASPHO, ASCO, and NNP. Currently, she is the nurse practitioner representative for ASCO Editorial Board, Nebraska Nurse Practitioner Nominating Committee Chair-Elect and serves as a member on the APSHO Communications Committee. 

Barbara Rogers, CRNP, MN, AOCN, ANP-BC
Adult Hematology-Oncology Nurse Practitioner
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Ms. Rogers is a Nurse Practitioner at Fox Chase Cancer Center in Philadelphia, Pennsylvania. She obtained her BSN from Trenton State College, her MN from UCLA and her post-master’s NP certificate from Temple University. Ms. Rogers has over 40 years of oncology experience with most of that time focused on the care of patients with hematologic malignancies. She has
authored many peer-reviewed journal articles and book chapters, as well as given many presentations related to the care of patients with hematologic malignancies and symptom management. Ms. Rogers has held leadership positions in multiple organizations such as serving on the ONS Board of Directors, Chair of the ONS Nominating Committee, and Chair of the Advanced Practice Test Development Committee of the Oncology Nursing Certification Corporation. Currently, she is a member of the Education Committee of the Advanced Practitioner Society for Hematology and Oncology (APSHO).

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:  
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Katherine L. Byar, MSN, ANP-BC, BMTCN–has no relevant financial relationships to disclose in relation to the content of this activity.

Matthew Lunning, DO–has disclosed that he is a consultant for Acrotech, ADC Therapeutics, AstraZeneca, BeiGene, BMS, Daiichi Sankyo, Janssen, Karyopharm, Kite, Kyowa Kirin, Legend, Morphosys, Myeloid Therapeutics, Novartis, Spectrum, and TG Therapeutics.
 
Authors/Presenters:
Katherine L. Byar, MSN, ANP-BC, BMTCN–has no relevant financial relationships to disclose in relation to the content of this activity.

Ian W. Flinn, MD, PhD–has disclosed that he is a consultant for AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Novartis, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincerx Pharma, and Yingli Pharmceuticals but his honorarium is issued to his institution, Sarah Cannon Research Institute. He receives grant/research support from AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, and Verastem but his honorarium is issued to his institution, Sarah Cannon Research Institute.

Amy L Goodrich, RN, MSN, CRNP-AC–has disclosed that she is a consultant/on the advisory board for Abbvie, AstraZeneca, Celgene, and Rigel.

Matthew Lunning, DO–has disclosed that he is a consultant for Acrotech, ADC Therapeutics, AstraZeneca, BeiGene, BMS, Daiichi Sankyo, Janssen, Karyopharm, Kite, Kyowa Kirin, Legend, Morphosys, Myeloid Therapeutics, Novartis, Spectrum, and TG Therapeutics.

Shazia K. Nakhoda, MD–has no relevant financial relationships to disclose in relation to the content of this activity.

Barbara Rogers, CRNP, MN, AOCN, ANP-BC–has disclosed that she is a consultant for ADCC Therapeutics, Cardinal Health, and Coherus. She is on the speakers' bureau for AstraZeneca and Coherus.

Julie Vose, MD, MBA–has disclosed that she is a consultant for Abbvie, Acerta Pharma/AstraZeneca, Conjupro Biotherapeutics, Genentech, Janssen/Pharmacyclics, Johnson and Johnson, Kite Pharma, Morphyosis, Oncternal, Roche, and Vaniam Group. She receives grant/research support from Acerta Pharma/AstraZeneca, Celgene/BMS, Epizyme, Incyte Corp., Kite Pharma, LOXO, Novartis, and Seattle Genetics, Inc.

Reviewer:
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.